Unmet Needs in Uncontrolled Gout Treatment (public)

What are needs unmet by the current treatment patterns for patients uncontrolled gout?

Unmet needs in uncontrolled gout include ongoing flares and tophi formation despite standard therapy, restricted treatment options for patients with kidney or heart disease, drug safety concerns, and barriers to optimal care management.

Abstract

Patients with uncontrolled gout face several challenges that current treatment patterns do not address. Studies report that patients with refractory or treatment‐failure gout continue to experience frequent flares, tophaceous deposits, and high healthcare use despite conventional urate‐lowering therapy. One set of papers finds that 15–32% of patients remain difficult to treat even with aggressive management.

Unmet needs include:

1. Persistent disease activity—with recurrent flares and tophi formation—despite standard therapy.
2. Limited safe and effective options for patients with comorbid conditions (notably chronic kidney and cardiovascular disease), given dosing constraints and increased adverse effects.
3. Safety and tolerability issues, such as immunogenicity and infusion reactions with agents like pegloticase.
4. Barriers to optimal management arising from poor treatment adherence, inadequate patient–provider communication, and clinical inertia.

These studies indicate that existing treatment strategies often fall short for patients with uncontrolled gout, leaving a need for approaches that directly address these clinical and management gaps.

Methods

We analyzed 40 sources from an initial pool of 997, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.

Screening Criteria

• Target Population: Uncontrolled, refractory, difficult-to-treat, or inadequately controlled gout patients.
• Unmet Needs Focus: Identification, description, or measurement of unmet clinical needs, treatment gaps, patient dissatisfaction, or suboptimal outcomes.
• Treatment and Outcomes: Reports on current treatment patterns, therapeutic approaches, management strategies, or patient outcomes.
• Adult Population: Focus on adult patients (≥18 years of age).
• Study Design and Data Quality: Randomized controlled trial, observational study, qualitative study, systematic review, or meta-analysis with original data.
• Patient Population Appropriateness: Avoid focus on well-controlled or successfully managed gout patients.
• Clinical Relevance: Avoid basic science, in vitro, animal research, or solely acute gout attacks.
• Study Size and Publication Type: Avoiding case reports or series with fewer than 10 patients, conference abstracts, editorials, or commentaries without original data.

Results

Characteristics of Included Studies

• 21 studies included uncontrolled, refractory, or treatment-failure gout.
• 22 studies included gout with comorbidities (such as chronic kidney disease, cardiovascular disease).
• 31 studies discussed urate-lowering therapy, including allopurinol, febuxostat, uricosurics, and pegloticase.
• 18 studies identified poor adherence or suboptimal management as an unmet need.

Thematic Analysis

Refractory and Difficult-to-Treat Gout

• A subset of patients experience persistent symptoms and flares despite aggressive therapy.

Treatment Limitations in Patients with Comorbidities

• Comorbidities are major barriers to effective gout management.

Safety and Tolerability Concerns with Current Therapies

• Safety issues are prevalent, particularly in patients with comorbidities.

Adherence Challenges

• Adherence to therapy is suboptimal due to various patient and provider factors.

References

1. R. Keenan. Limitations of the Current Standards of Care for Treating Gout.
2. T. Pascart, F. Lioté. Gout: State of the art after a decade of developments.
3. P. Richette et al. 2014. Updated EULAR evidence-based recommendations for gout management.